Artificial Intelligence based Modern Approaches to Diagnose Alzheimer s
Open Access
- 28 February 2022
- journal article
- Published by Lattice Science Publication (LSP) in Indian Journal of Artificial Intelligence and Neural Networking
- Vol. 2 (2), 1-14
- https://doi.org/10.54105/ijainn.b1045.022222
Abstract
In current times the level at which Alzheimer’s disease is rising is at an alarming rate. This rise points to the need for much more accurate and faster modes of diagnosis that the country wants. Artificial intelligence can resolve this issue as it uses extensive human surveys and real-time machine medicine monitors. The use of biomarkers that work on detecting unusual changes in the brain and the spectrochemical analysis of blood that works on the principle of vibrational spectroscopy Inclusive of Raman spectroscopy and FTIR cannot be used at a large scale. The underemployment of these methods includes the requirement of highly trained professionals and the heterogeneous nature of the human population. Therefore, the following approaches may be employed to overcome these benefits and give individuals optimal health solutions; Random Forest technique, etc., artificial neural network. When the talk is shifted towards treating Alzheimer’s, there is no such drug to treat it thoroughly. Symptomatic treatment options are available based on specific known receptors of Alzheimer’s etiology. Artificial intelligence has also taken a pioneering step to fill this void. With its help, we can identify a lot more receptors influenced upon Alzheimer’s advent. Once these newly found receptors are considered, better symptomatic treatment can be provided. Drug classes like NMDA receptor antagonists, Statins, and Antipsychotics are readily available options for managing disease, but all of these have a low safety index and other side effects like bleeding and psychosis. Newly re-purposed drugs like Acitretin and minocycline etc., have minimalistic side effects and high safety margin, making them a better choice in the diseased state. After Artificial intelligence has entered the market, the fields of diagnostics and therapeutics and taken the most advantage of it alongside administration and regulation, therefore, this AI is a boon in the medical industry as it can help manage medicine-based disease registries and population management when it comes to Alzheimer’s diagnosis and treatment.Keywords
This publication has 100 references indexed in Scilit:
- Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease modelProceedings of the National Academy of Sciences of the United States of America, 2012
- Nonlinear time course of brain volume loss in cognitively normal and impaired eldersNeurobiology of Aging, 2012
- Carvedilol as a potential novel agent for the treatment of Alzheimer's diseaseNeurobiology of Aging, 2011
- Effects of hardware heterogeneity on the performance of SVM Alzheimer's disease classifierNeuroImage, 2011
- The dynamics of Alzheimer's disease biomarkers in the Alzheimer's Disease Neuroimaging Initiative cohortNeurobiology of Aging, 2010
- Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascadeThe Lancet Neurology, 2010
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD miceExperimental Neurology, 2007
- Alzheimer's diseaseThe Lancet, 2006
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004